Safinamide

Introduction Overview

Generic Name

safinamide

Brand Name

Xadago

Dosage Form

Oral tablet

Drug Class

Dopaminergic antiparkinsonism agents (Monoamine oxidase type B inhibitor - MAO-B inhibitor)

Pharmacokinetics

Absorption:
Safinamide is rapidly absorbed following oral administration. Peak plasma concentrations are generally reached within 2 to 4 hours after dosing. The absolute bioavailability of safinamide tablets is approximately 95%, indicating efficient systemic absorption. Food intake does not significantly affect the bioavailability, allowing dosing with or without food. The high oral bioavailability favors consistent plasma drug levels crucial in managing Parkinson’s disease symptoms.

Distribution:
Safinamide exhibits an apparent volume of distribution of approximately 165 L, suggesting extensive tissue distribution beyond the vascular compartment. The protein binding of safinamide is moderate, about 88–90%, primarily bound to albumin. Safinamide crosses the blood-brain barrier effectively, which is essential for exerting its therapeutic effects in the central nervous system. Distribution into the central nervous system allows safinamide to inhibit MAO-B enzymes in the brain, augmenting dopaminergic activity.

Metabolism:
Safinamide undergoes extensive hepatic metabolism primarily via non-cytochrome P450 enzymes including amidase hydrolase and glucuronidation pathways. The major metabolites are pharmacologically inactive. The drug does not significantly inhibit or induce cytochrome P450 enzymes, reducing potential for common metabolic drug interactions. Approximately 90% of an administered dose is metabolized before elimination, underscoring the liver’s role in safinamide clearance.

Elimination:
Safinamide and its metabolites are eliminated primarily via renal excretion (~76%) and fecal routes (~18%). The half-life of safinamide is approximately 20–26 hours, allowing once-daily dosing. Renal clearance accounts for elimination of metabolites; intact safinamide is minimally excreted unchanged in the urine. Caution is advised in patients with severe hepatic impairment as impaired metabolism can increase plasma exposure. No dose adjustment is required in mild to moderate renal impairment based on pharmacokinetic data.

Overall, safinamide demonstrates pharmacokinetic properties supportive of stable plasma levels with once-daily dosing, significant central nervous system penetration, and manageable elimination pathways, facilitating its adjunct role in Parkinson's disease therapy.

Dosage Forms

Available Dosage Forms:
Xadago is commercially available as oral tablets in the following strengths: 50 mg and 100 mg. These tablets are formulated for once-daily administration.

Dosages for Adults and Adolescents:
For Parkinson's disease patients experiencing "wearing-off" episodes, the initial recommended dose is 50 mg orally once daily. After two weeks, the dose may be increased to 100 mg once daily based on individual response and tolerability. The maximum recommended dose is 100 mg per day. Higher doses have not demonstrated additional clinical benefit and are associated with increased adverse reactions.

Specific Patient Populations:
Safinamide should be used with caution in patients with hepatic impairment. It is contraindicated in severe liver disease due to significantly increased drug exposure and risk of toxicity. No dose adjustments are typically necessary in patients with mild or moderate hepatic impairment. Pharmacokinetic data show no requirement for adjustment in renal impairment.

Clinical guidelines emphasize that Xadago must be used as an adjunctive therapy with levodopa/carbidopa and should not be used as monotherapy. Consistency in dosing time supports steady dopaminergic activity and optimal management of motor fluctuations in Parkinson’s disease.

Summary of Dosage Forms:
- Oral tablets: 50 mg and 100 mg
- Administered orally once daily
- Used only in combination with levodopa/carbidopa
- Dose initiation at 50 mg, titration to 100 mg if tolerated

Mechanism Of Action

Safinamide, the active ingredient in Xadago, is a selective, reversible inhibitor of monoamine oxidase type B (MAO-B), an enzyme responsible for the catabolism of dopamine in the brain. By inhibiting MAO-B, safinamide reduces the breakdown of dopamine, thereby increasing and prolonging its availability in the synaptic cleft. Elevated dopamine levels improve dopaminergic neurotransmission, which is deficient in Parkinson’s disease, addressing key motor symptoms such as bradykinesia and rigidity.

In addition to MAO-B inhibition, safinamide exhibits non-dopaminergic mechanisms that contribute to its clinical efficacy. It modulates glutamate release by blocking voltage-dependent sodium channels and inhibiting calcium channels, leading to reduced excitotoxic glutamatergic neurotransmission, which may play a role in motor complications of Parkinson’s disease. This dual mechanism influences both dopaminergic and glutamatergic pathways, potentially improving symptoms including levodopa-induced dyskinesia and motor fluctuations.

Safinamide’s reversible inhibition distinguishes it from other irreversible MAO-B inhibitors like selegiline and rasagiline. This reversible binding allows greater safety in terms of dietary tyramine interactions and drug–drug interactions, although caution with coadministered serotonergic drugs is still warranted.

Clinical studies demonstrate that safinamide as adjunct therapy to levodopa/carbidopa enhances 'on' time without troublesome dyskinesia, improves motor function, and reduces 'off' time episodes. The unique combination of dopaminergic enhancement and glutamate modulation provides a multifaceted approach to symptom management in Parkinson’s disease, representing a valuable addition to conventional treatments.

Pharmacological Actions

Selective, reversible inhibition of monoamine oxidase type B (MAO-B), leading to increased dopamine availability in the brain.
Modulation of glutamate release via voltage-gated sodium and calcium channel blockade, contributing to reduced excitotoxicity.
Adjunctive enhancement of levodopa's efficacy in Parkinson’s disease by prolonging dopamine activity.
Improvement of motor fluctuations and reduction of 'off' episodes in Parkinson's patients.
Neurochemical modulation with minimal action on peripheral monoamine oxidase type A (MAO-A), limiting systemic adverse effects.
Reduction in abnormal involuntary movements associated with long-term levodopa use through glutamatergic pathway effects.
Lack of significant cytochrome P450 enzyme induction or inhibition, decreasing propensity for drug-drug interactions.
Once-daily dosing due to favorable pharmacokinetics and sustained pharmacodynamic effects.
Reversible MAO-B inhibition confers safety advantages over irreversible inhibitors regarding tyramine sensitivity.
Adjunct neuroprotective effects hypothesized based on glutamate modulation and antioxidant properties, although clinical proof is pending.

Therapeutic Or Clinical Uses

Adjunctive treatment with levodopa/carbidopa for managing "wearing-off" motor fluctuations in Parkinson's disease.
Reduction of 'off' episodes characterized by muscle stiffness and loss of motor control in Parkinson’s patients.
Improvement in overall motor function and daily symptom control when used with standard dopaminergic therapy.
Management of Parkinson’s disease symptoms in patients not adequately controlled by levodopa alone.
Potential reduction in levodopa-induced dyskinesia through modulation of glutamatergic pathways.
Treatment indicated for adult patients with Parkinson’s disease experiencing motor fluctuations.
Useful in patients who require additional symptomatic control of Parkinson's disease without increasing levodopa dose.
Provision of a once-daily oral treatment option that complements existing dopaminergic agents.
Alternative for patients intolerant to other MAO-B inhibitors due to its reversible inhibition and safety profile.
Clinical studies support its use for improving 'on' time duration without increasing troublesome dyskinesia.

Side Or Adverse Effects

Involuntary muscle movements (dyskinesia), often mild to moderate in severity.
Falls resulting from motor instability or dizziness.
Nausea, which may be transient during treatment initiation.
Insomnia and other sleep disturbances.
Confusion, agitation, or hallucinations, particularly in elderly patients or those with pre-existing cognitive impairment.
Increased blood pressure leading to hypertensive episodes; patients should monitor blood pressure regularly.
Twitching or uncontrolled muscle movements, sometimes indicating central nervous system effects.
Increased sexual urges or unusual compulsive behaviors such as gambling or spending.
Allergic reactions including rash, hives, and rare but serious hypersensitivity reactions.
Symptoms of serotonin syndrome when combined with serotonergic drugs, such as fever, sweating, and overactive reflexes.
Nausea, vomiting, and diarrhea as gastrointestinal side effects.
Seizures have been reported rarely and require immediate medical attention.
Visual disturbances or changes, requiring ophthalmologic evaluation if persistent.
Potential worsening of psychiatric symptoms including psychosis or bipolar disorder manifestations.
Narcolepsy-like episodes or excessive daytime sleepiness leading to sudden sleep onset.

Precautions

Contraindicated in patients with severe hepatic impairment due to increased risk of toxicity.
Avoid concomitant use with other MAO inhibitors or serotonergic agents to reduce risk of serotonin syndrome.
Monitor blood pressure regularly due to risk of hypertensive crises, especially in patients with pre-existing hypertension.
Use caution in patients with a history of psychotic disorders, bipolar disorder, or schizophrenia.
Patients should be informed about the risk of sudden daytime sleep onset and cautioned against driving or operating machinery until tolerance is established.
Caution advised in patients with retinal disorders, as visual changes may occur.
Avoid high-tyramine-containing foods and certain alcoholic beverages to prevent hypertensive reactions.
Not recommended for use as monotherapy; must be administered adjunctively with levodopa/carbidopa.
Patients should report unusual urges or compulsive behaviors promptly for reevaluation.
No adequate studies in pregnant women; use only if benefit justifies potential risk and avoid breastfeeding during therapy.
Caution with concomitant use of opioids or narcotics due to increased risk of adverse effects.
Adjust dosage carefully in the elderly or those with multiple comorbidities due to increased side effect sensitivity.
Regular clinical monitoring for motor symptoms and adverse neurological effects is essential.
Evaluate renal and hepatic function prior to and during treatment to ensure safe use.
Educate patients on recognizing signs of serious adverse reactions such as serotonin syndrome or hypertensive crises.

Warnings

Do not use Xadago in patients with severe liver disease; it is contraindicated.
Avoid concomitant use with other MAO inhibitors, certain antidepressants, and opioids due to risk of serious, potentially fatal reactions.
Avoid foods high in tyramine during treatment and for at least 14 days after discontinuation to prevent hypertensive crisis.
Patients may experience sudden sleep onset during ordinary daily activities, increasing risk for accidents; avoid driving until response to drug is known.
Patients with a history of psychiatric disorders could experience worsening symptoms or new onset of hallucinations or psychosis.
Potential for increased blood pressure necessitates close monitoring, especially in patients with hypertension.
Use with caution in patients with pre-existing impulse control disorders; safinamide may increase compulsive behaviors.
Not established as safe for use during pregnancy or lactation.
Serotonin syndrome risk exists when combined with serotonergic agents or certain medications like dextromethorphan or tramadol.
Overdose may result in serious central nervous system effects; emergency medical attention should be sought.
Abrupt withdrawal is not typically required, but clinical monitoring during discontinuation is advised.
Do not initiate treatment if other contraindicated medications have been administered within the previous 14 days.
Observed neuropsychiatric adverse effects warrant individualized risk-benefit assessment.
Patient education on recognizing signs of allergic reactions (e.g., swelling, difficulty breathing) is crucial.
Concomitant use with dopaminergic antagonists should be avoided as it may reduce therapeutic efficacy.

Contraindication

Severe hepatic impairment or severe liver disease.
Known hypersensitivity or allergy to safinamide or any component of the formulation.
Use within 14 days before or after treatment with other monoamine oxidase inhibitors (MAOIs), including isocarboxazid, phenelzine, rasagiline, selegiline, tranylcypromine, and methylene blue injection.
Concomitant use with opioids such as meperidine (Demerol), methadone, propoxyphene, tramadol, and related narcotic medications.
Use with serotonergic antidepressants including certain tricyclics and SNRIs like amitriptyline, desipramine, duloxetine, venlafaxine, and others unless closely monitored.
Concurrent administration with sympathomimetic agents like amphetamines, methylphenidate, and cyclobenzaprine.
Use with cough suppressants containing dextromethorphan.
Concomitant treatment with St. John's Wort due to risk of serotonin syndrome.
Known or suspected pheochromocytoma or other tumors known to secrete catecholamines.
Patients with a history of severe psychiatric illness that may be exacerbated by dopaminergic agents.
Use in patients with untreated or uncontrolled hypertension.
Patients with history of retinal disease should avoid safinamide unless benefits outweigh risks.
Patients taking dopaminergic antagonists as safinamide efficacy may be compromised.

Drug Interactions

Interaction with other MAO inhibitors results in potentially fatal hypertensive crisis or serotonin syndrome.
Combination with serotonergic drugs like SSRIs, SNRIs, tricyclic antidepressants, or certain opioids increases risk of serotonin syndrome.
Concomitant use with opioids such as tramadol and meperidine contraindicated due to serious adverse CNS effects.
Amphetamines and other sympathomimetic agents may cause dangerous increases in blood pressure when used with Xadago.
Dextromethorphan-containing cough medications can increase risk of serotonin syndrome when combined with safinamide.
Cyclobenzaprine and methylphenidate pose increased risk of hypertensive episodes and CNS side effects when combined.
St. John's wort may potentiate serotonergic effects leading to serotonin syndrome.
Safinamide may interact with imatinib, irinotecan, lapatinib, methotrexate, metoclopramide, mitoxantrone, rosuvastatin, sulfasalazine, and topotecan based on metabolic pathways, requiring monitoring.
Potential for interaction with dopaminergic antagonists that may reduce efficacy of safinamide and levodopa.
Foods rich in tyramine can provoke hypertensive crises when combined with safinamide due to MAO-B inhibition.
No significant interactions with cytochrome P450 substrates; however, clinical monitoring is recommended when starting or stopping concurrent therapies.
Concomitant use with neuroleptics may negate therapeutic effects and exacerbate Parkinsonian symptoms.
Concurrent administration with blood pressure-altering agents requires cautious monitoring.
Interaction with herbal supplements other than St. John's Wort is possible; patients should disclose all supplements.
Alcohol may exacerbate CNS adverse effects and should be used with caution.

Preparations Of The Drug

Xadago is formulated as oral tablets available in 50 mg and 100 mg strengths.
Tablets are administered once daily, with or without food.
Provided in tamper-evident bottles with child-resistant caps to ensure medication safety.
Supplied in unit-dose packaging in some markets to promote adherence and dosing accuracy.
Storage conditions require room temperature away from moisture and heat to maintain stability.
No approved liquid or injectable formulations are currently available.
Tablets do not require special handling or reconstitution.
The formulation contains excipients that do not affect tolerability or absorption significantly.
Generic formulations of safinamide tablets (Xadago) are available in some jurisdictions.
Packaging includes patient information leaflets detailing dosage, side effects, and precautions.
Prescribing information specifies co-administration only with levodopa/carbidopa therapy.
Labeling highlights black box warnings for severe liver disease contraindication and potential drug interactions.
Instructions emphasize adherence to once-daily dosing to maintain therapeutic plasma levels.
Safe disposal recommendations are provided to minimize environmental and accidental exposure risks.
Some formulations include specific markings or imprint codes for identification and anti-counterfeit measures.